A. Yamamoto

发表

Regression of atherosclerosis in humans by lowering serum cholesterol.

A. Yamamoto, A. Yamamoto, 1991, Atherosclerosis.

Angiographic Intervention Trial Using Hmg Coa Reductase Inhibitor to Evaluate Retardation of Obstructive Multiple Atheroma in West Japan (ATHEROMA Study): Rationale, Design and Baseline

M. Nobuyoshi, M. Nakashima, A. Yamamoto, 2002, Journal of cardiovascular risk.

Three-year follow-up results of angiographic intervention trial using an HMG-CoA reductase inhibitor to evaluate retardation of obstructive multiple atheroma (ATHEROMA) study.

M. Nobuyoshi, H. Yokoi, A. Yamamoto, 2005, Circulation journal : official journal of the Japanese Circulation Society.

Probucol prevents lipid storage in macrophages.

S. Yokoyama, S. Takaichi, A. Yamamoto, 1986, Atherosclerosis.

Structure and expression of mouse apolipoprotein E gene.

K. Horiuchi, M. Menju, A. Yamamoto, 1989, Journal of biochemistry.

Effect of lipid particle size on association of apolipoproteins with lipid.

S. Yokoyama, A. Yamamoto, S. Tajima, 1983, The Journal of biological chemistry.

Effects of probucol on homozygous cases of familial hypercholesterolemia.

Y. Matsuzawa, A. Yamamoto, K. Hirobe, 1983, Atherosclerosis.

Tissue factor pathway inhibitor activity in human plasma. Measurement of lipoprotein-associated and free forms in hyperlipidemia.

M. Harada‐Shiba, T. Abumiya, H. Kato, 1995, Arteriosclerosis, thrombosis, and vascular biology.

Impact of statin treatment on the clinical fate of heterozygous familial hypercholesterolemia.

S. Yokoyama, Y. Yoshimasa, H. Tomoike, 2010, Journal of atherosclerosis and thrombosis.

Hyperlipoproteinemia as a risk factor for ischemic heart disease.

K. Haze, A. Yamamoto, K. Hiramori, 1990, Japanese circulation journal.

Selective Removal of Low Density Lipoprotein by Plasmapheresis in Familial Hypercholesterolemia

S. Yokoyama, A. Yamamoto, M. Satani, 1985, Arteriosclerosis.

Effects of simvastatin on the number and composition of apoproteinB-containing lipoproteins in hypercholesterolemia: analysis of apoproteinB in each lipoprotein fraction by highly sensitive latex method.

A. Yamamoto, M. Suzuki, Y. Harano, 1996, Endocrine journal.

Low density lipoprotein (LDL) binding affinity for the LDL receptor in hyperlipoproteinemia.

A. Yamamoto, T. Yamamura, Y. Toyota, 1994, Atherosclerosis.

LDL-apheresis; potential procedure for prevention and regression of atheromatous vascular lesion.

S. Yokoyama, A. Yamamoto, M. Satani, 1987, Japanese circulation journal.

Analysis of serum lipid levels in Japanese men and women according to body mass index. Increase in risk of atherosclerosis in postmenopausal women. Research Group on Serum Lipid Survey 1990 in Japan.

Y. Matsuzawa, T. Kita, H. Mabuchi, 1999, Atherosclerosis.

Serum lipid levels in elementary and junior high school children and their relationship to relative weight.

Y. Matsuzawa, S. Yokoyama, A. Yamamoto, 1988, Preventive medicine.

Polymorphisms in four genes related to triglyceride and HDL-cholesterol levels in the general Japanese population in 2000.

Y. Ouchi, Y. Matsuzawa, T. Kita, 2005, Journal of atherosclerosis and thrombosis.

Leg edema, ST-T abnormalities, and high BNP values are important signs of heart failure in the elderly.

A. Yamamoto, A. Kawaguchi, M. Mankumo, 2001, Archives of gerontology and geriatrics.

HYPERCHOLESTEROLEMIC VALVULOPATHY : CHARACTERISTIC CARDIOVASCULAR MANIFESTATION IN HOMOZYGOUS AND HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA

K. Miyatake, A. Yamamoto, A. Kawaguchi, 2017 .

Serum lipid survey and its recent trend in the general Japanese population in 2000.

Y. Ouchi, Y. Matsuzawa, T. Kita, 2005, Journal of atherosclerosis and thrombosis.

Clinical effects of rosuvastatin, a new HMG-CoA reductase inhibitor, in Japanese patients with primary hypercholesterolemia: an early phase II study.

Y. Matsuzawa, J. Sasaki, K. Arakawa, 2002, Journal of atherosclerosis and thrombosis.

Apheresis technology for prevention and regression of atherosclerosis: an overview.

M. Harada‐Shiba, A. Yamamoto, A. Kawaguchi, 1997, Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis.

Effects of probucol on xanthomata regression in familial hypercholesterolemia.

T. Funahashi, Y. Matsuzawa, S. Yokoyama, 1986, The American journal of cardiology.

Clinical features of familial hypercholesterolemia.

T. Funahashi, S. Yokoyama, T. Kamiya, 1989, Arteriosclerosis.

A little more information about aggravation of probucol-induced HDL-reduction by clofibrate.

S. Yokoyama, A. Yamamoto, T. Kurasawa, 1988, Atherosclerosis.

Effect of probucol on macrophages, leading to regression of xanthomas and atheromatous vascular lesions.

J. Wakasugi, S. Takaichi, A. Yamamoto, 1988, The American journal of cardiology.

Intensive Drug Treatment for Familial Hypercholesterolemia

S. Yokoyama, A. Yamamoto, T. Yamamura, 1987 .

Effect of Long-term Treatment with Probucol on Familial Hypercholesterolemia (An Interim Report)

Y. Matsuzawa, M. Koga, A. Yamamoto, 1984 .

Rate of cholesteryl ester transfer between high and low density lipoproteins in human serum and a case with decreased transfer rate in association with hyperalphalipoproteinemia.

S. Yokoyama, A. Yamamoto, T. Yamamura, 1985, Journal of biochemistry.

A point mutation of low-density-lipoprotein receptor causing rapid degradation of the receptor.

T. Funahashi, T Funahashi, A. Yamamoto, 1992, European journal of biochemistry.

A novel point mutation in a splice acceptor site of intron 1 of the human low density lipoprotein receptor gene which causes severe hypercholesterolemia: An unexpected absence of exon skipping

T. Funahashi, Y. Matsuzawa, T. Maruyama, 1998, Human mutation.

Response of 3-hydroxy-3-methylglutaryl CoA reductase to l-triiodothyronine in cultured fibroblasts from FH homozygotes.

M. Harada‐Shiba, A. Yamamoto, S. Tajima, 1995, Atherosclerosis.

Analysis of apolipoprotein E5 gene from a patient with hyperlipoproteinemia.

A. Yamamoto, T. Yamamura, S. Tajima, 1988, Journal of biochemistry.

New mutants of apolipoprotein E associated with atherosclerotic diseases but not to type III hyperlipoproteinemia.

T. Sumiyoshi, A. Yamamoto, K. Hiramori, 1984, The Journal of clinical investigation.

Analysis of a recycling-impaired mutant of low density lipoprotein receptor in familial hypercholesterolemia.

T. Funahashi, A. Yamamoto, S. Tajima, 1989, The Journal of biological chemistry.

Homozygous familial hypercholesterolemia mutant with a defect in internalization of low density lipoprotein.

A. Yamamoto, T. Yamamura, S. Tajima, 1981, Proceedings of the National Academy of Sciences of the United States of America.

Determination by the SRID Method of Normal Values of Serum Apolipoproteins (A-I, A-II, B, C-II, C-III, and E) in Normolipidemic Healthy Japanese Subjects

Y. Matsuzawa, J. Sasaki, Y. Akanuma, 1986 .

Defining patients at extremely high risk for coronary artery disease in heterozygous familial hypercholesterolemia.

T. Okamura, S. Yokoyama, M. Harada‐Shiba, 2012, Journal of atherosclerosis and thrombosis.

Siblings with normal LDL receptor activity and severe hypercholesterolemia.

S. Yokoyama, M. Harada‐Shiba, S. Tajima, 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.

Apheresis technology for prevention and regression of atherosclerosis.

M. Harada‐Shiba, A. Yamamoto, A. Kawaguchi, 2001, Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis.

No severe bottleneck during human evolution: evidence from two apolipoprotein C-II deficiency alleles.

W. Li, A. Gotto, L. Chan, 1991, American journal of human genetics.

Familial type I hyperlipoproteinemia caused by apolipoprotein C-II deficiency.

A. Yamamoto, H. Sudo, T. Yamamura, 1979, Atherosclerosis.

The effect of atorvastatin on serum lipids and lipoproteins in patients with homozyous familial hypercholesterolemia undergoing LDL-apheresis therapy.

M. Harada‐Shiba, A. Yamamoto, A. Kawaguchi, 2000, Atherosclerosis.

The effect of atorvastatin on serum lipids and lipoproteins in patients with homozyous familial hypercholesterolemia undergoing LDL-apheresis therapy

M. Harada‐Shiba, A. Yamamoto, A. Kawaguchi, 2000 .

Study on the Mechanism of Probucol Action to Familial Hypercholesterolemia: -Reduction of HDL-cholesterol Might Be a Favorable Change for Lipoprotein Metabolism?-@@@―HDL-コレステロールの低下は好ましい変化である?―

T. Funahashi, Y. Matsuzawa, A. Yamamoto, 1986 .

Changes of serum total cholesterol and triglyceride levels in normal subjects in Japan in the past twenty years. Research committee on familial hyperlipidemia in Japan.

H. Sekimoto, H. Fukuzaki, Y. Goto, 1983, Japanese circulation journal.

Triglyceride and glucose intolerance as a risk factor for coronary heart disease.

Y. Matsuzawa, A. Yamamoto, A. Kawaguchi, 1991, Cardiology.

Polymorphisms of apolipoprotein e and methylenetetrahydrofolate reductase in the Japanese population.

Y. Ouchi, Y. Matsuzawa, T. Kita, 2007, Journal of atherosclerosis and thrombosis.

Prevalence of the metabolic syndrome in elderly and middle-aged Japanese

Y. Ouchi, Y. Matsuzawa, T. Kita, 2010 .

Serum Lipid Levels in School Boys and Girls in Shinjo District

Y. Matsuzawa, S. Yokoyama, Y. Kawai, 1982 .

Regression of Coronary Atherosclerosis by LDL-Apheresis

T. Nishide, T. Teramoto, Y. Goto, 1993 .

Angiographic and pathological studies on regression of coronary atherosclerosis of FH patients who received LDL-apheresis treatment.

A. Yamamoto, N. Koga, Y. Iwata, 2008, Artificial organs.

Mutations of the low density lipoprotein receptor in Japanese kindreds with familial hypercholesterolemia

T. Funahashi, Y. Matsuzawa, A. Yamamoto, 1988, Human Genetics.

Mutations of the low density lipoprotein receptor in familial hypercholesterolemia--analysis of 21 homozygotes.

A. Yamamoto, 1988, Japanese journal of medicine.

Rapid purification of human plasma lipid transfer proteins.

S. Yokoyama, A. Yamamoto, T. Ohnishi, 1990, Journal of lipid research.

Changes in Coagulation Factors by Passage through a Dextran Sulfate Cellulose Column during Low-Density Lipoprotein Apheresis

M. Harada‐Shiba, M. Kuramochi, T. Omae, 1992, The International journal of artificial organs.

Concentration and distribution of apolipoproteins A-I and E in normolipidemic, WHHL and diet-induced hyperlipidemic rabbit sera.

A. Yamamoto, H. Mezdour, T. Yamamura, 1992, Biochimica et biophysica acta.

Induction of acetylated low density lipoprotein receptor and suppression of low density lipoprotein receptor on the cells of human monocytic leukemia cell line (THP-1 cell).

S. Yokoyama, A. Yamamoto, H. Hara, 1987, Biochemical and biophysical research communications.

Measurement of the free form of TFPI antigen in hyperlipidemia. Relationship between free and endothelial cell-associated forms of TFPI.

M. Harada‐Shiba, H. Kato, K. Enjyoji, 1996, Arteriosclerosis, thrombosis, and vascular biology.

Cholesterol and Postheparin Lipoprotein Lipase but Proportional to Apolipoprotein A-II Intravascular Free Tissue Factor Pathway Inhibitor Is Inversely Correlated With HDL

M. Yamagishi, H. Nonogi, Y. Miyao, 1999 .

A new isoform of apolipoprotein E--apo E-5--associated with hyperlipidemia and atherosclerosis.

A. Yamamoto, K. Hiramori, T. Yamamura, 1984, Atherosclerosis.

A Japanese family with high density lipoprotein deficiency.

S. Yokoyama, S. Tajima, A. Yamamoto, 1983, Atherosclerosis.

Genetic but not diet-induced hypercholesterolemia causes low apolipoprotein A-IV level in rabbit sera.

A. Yamamoto, H. Mezdour, T. Yamamura, 1995, Atherosclerosis.

Behavior of human apolipoprotein E in aqueous solutions and at interfaces.

S. Yokoyama, Y. Kawai, A. Yamamoto, 1985, The Journal of biological chemistry.

Association of apolipoprotein E with the low density lipoprotein receptor: demonstration of its co-operativity on lipid microemulsion particles.

T. Funahashi, S. Yokoyama, A. Yamamoto, 1989, Journal of biochemistry.

Expression of the apolipoprotein E gene in a human macrophage-like cell line, THP-1.

M. Menju, A. Yamamoto, S. Tajima, 1989, Journal of biochemistry.

Supravalvular Aortic Stenosis and Coronary Ostial Stenosis in Familial Hypercholesterolemia: Two‐dimensional Echocardiographic Assessment

S. Beppu, A. Yamamoto, H. Sakakibara, 1983, Circulation.

Phagocytic degradation of chylomicron remnants by fibroblasts from subjects with homozygous familial hypercholesterolaemia.

M. Harada‐Shiba, A. Yamamoto, A. Kawaguchi, 1997, Clinical science.

Escape phenomenon occurs by lowering cholesterol with a hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitor in patients with familial hypercholesterolemia.

S. Yokoyama, A. Yamamoto, T. Yamamura, 1988, Atherosclerosis.

Histochemical Characterization of Low Density Lipoprotein Receptors in Internalization‐Defective Familial Hypercholesterolemia

A. Yamamoto, S. Tajima, Y. Miyake, 1985, Arteriosclerosis.

Combined drug therapy--cholestyramine and compactin--for familial hypercholesterolemia.

Y. Matsuzawa, S. Yokoyama, A. Yamamoto, 1984, International journal of clinical pharmacology, therapy, and toxicology.

Lipoprotein (a) in ischemic heart disease and cerebrovascular disease.

X. Yang, K. Haze, A. Yamamoto, 1995, Journal of atherosclerosis and thrombosis.

Assessment of the biocompatibility and long-term effect of LDL-apheresis by dextran sulfate-cellulose column.

A. Yamamoto, A. Kawaguchi, S. Kojima, 2008, Artificial organs.

A single point mutation in the splice donor site of the low-density-lipoprotein-receptor gene produces intron read-through, exon-skipped and cryptic-site-utilized transcripts.

T. Funahashi, Y. Matsuzawa, T. Maruyama, 1995, European journal of biochemistry.

Characterization of apolipoprotein E7 (Glu(244)-->Lys, Glu(245)--->Lys), a mutant apolipoprotein E associated with hyperlipidemia and atherosclerosis.

A. Yamamoto, T. Yamamura, L. Dong, 1999, Journal of lipid research.

Hypercholesterolemic Valvulopathy: An Aspect of Malignant Atherosclerosis

C. Yutani, A. Yamamoto, A. Kawaguchi, 2003 .

Comparison of apolipoprotein C-II-deficient triacylglycerol-rich lipoproteins and trioleoylglycerol/phosphatidylcholine-stabilized particles as substrates for lipoprotein lipase.

S. Yokoyama, R. Jackson, A. Yamamoto, 1986, Biochimica et biophysica acta.

Mechanism of action of lipoprotein lipase on triolein particles: effect of apolipoprotein C-II.

S. Yokoyama, A. Yamamoto, S. Tajima, 1984, Journal of biochemistry.

The effect of ezetimibe on serum lipids and lipoproteins in patients with homozygous familial hypercholesterolemia undergoing LDL-apheresis therapy.

M. Harada‐Shiba, A. Yamamoto, H. Kato, 2006, Atherosclerosis.

Effects of apolipoprotein C-II (apoC-II) on the lipolysis of very low density lipoproteins from apoC-II deficient patients.

J. Johnson, K. Shirai, R. Jackson, 1981, Metabolism: clinical and experimental.

Cells of a human monocytic leukemia cell line (THP-1) synthesize and secrete apolipoprotein E and lipoprotein lipase.

S. Tsuchiya, A. Yamamoto, S. Tajima, 1985, Biochemical and biophysical research communications.

Long-term Effect of LDL-Apheresis on Familial Hypercholesterolemia Homozygotes

M. Harada‐Shiba, A. Yamamoto, A. Kawaguchi, 2000 .

Risk Factors for Atherosclerotic Vascular Diseases with Special Reference to the Relationship between Apolipoprotein E Mutations and Hyperlipidemia

S. Tajima, A. Yamamoto, T. Yamamura, 1990, Annals of the New York Academy of Sciences.

Plasmapheresis for Prevention and Regression of Coronary Atherosclerosis

M. Harada‐Shiba, M. Takamiya, A. Yamamoto, 1994, Annals of the New York Academy of Sciences.

Analysis of apolipoprotein E7 (apolipoprotein E-Suita) gene from a patient with hyperlipoproteinemia.

M. Menju, A. Yamamoto, T. Yamamura, 1989, Journal of biochemistry.

Plasma constituents other than low-density lipoprotein adsorbed by dextran-sulfate column.

M. Harada‐Shiba, A. Yamamoto, S. Kojima, 1997, Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis.

Hyperbetalipoproteinemia with small low-density lipoprotein, a characteristic disorder of lipoprotein in essential hypertension.

Y. Hara, A. Yamamoto, M. Ikebuchi, 1995, Journal of diabetes and its complications.

The process of dissolving apolipoprotein A-I in an aqueous buffer.

S. Yokoyama, A. Yamamoto, S. Tajima, 1982, Journal of biochemistry.

Prevalence of hypertension in CHD patients in the asia-pacific region: the aspac study

A. Dans, A. Keech, S. MacMahon, 2000 .

Fatty Acid Composition of Phospholipids in Human Serum Lipoprotein Fractions

Y. Matsuzawa, A. Yamamoto, T. Yamamura, 1977 .

Hypercholesterolemic valvulopathy: an aspect of malignant atherosclerosis.

C. Yutani, A. Yamamoto, A. Kawaguchi, 2003, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

Effects of a new free radical scavenger, 2-aminomethyl4-tert-butyl-6-propionylphenol (ONO-3144), in two diabetic animal models

A. Yamamoto, M. Tsushima, S. Nambu, 1988 .

A method for direct incorporation of radiolabeled cholesteryl ester into human plasma low-density-lipoproteins: preparation of tracer substrate for cholesteryl ester transfer reaction between lipoproteins.

S. Yokoyama, A. Yamamoto, O. Nishikawa, 1986, Journal of biochemistry.

Characteristic cardiovascular manifestation in homozygous and heterozygous familial hypercholesterolemia.

C. Yutani, K. Miyatake, A. Yamamoto, 1999, American heart journal.

Exogenous supply of artificial lipoproteins does not decrease susceptibility to atherosclerosis in cholesterol-fed rabbits.

A. Yamamoto, H. Mezdour, T. Yamamura, 1995, Atherosclerosis.

Effect of nafamostat mesilate on bradykinin generation during low-density lipoprotein apheresis using a dextran sulfate cellulose column.

M. Harada‐Shiba, M. Kuramochi, T. Omae, 1991, ASAIO transactions.

Acquisition of Secretion of Transforming Growth Factor-β1 Leads to Autonomous Suppression of Scavenger Receptor Activity in a Monocyte-Macrophage Cell Line, THP-1*

M. Harada‐Shiba, S. Tajima, A. Yamamoto, 1998, The Journal of Biological Chemistry.

Specific sorbent of apolipoprotein B-containing lipoproteins for plasmapheresis. Characterization and experimental use in hypercholesterolemic rabbits.

S. Yokoyama, A. Yamamoto, R. Hayashi, 1984, Arteriosclerosis.

Evaluation of Albumin Loss During Low‐density Lipoprotein Apheresis

M. Kuramochi, A. Yamamoto, S. Kojima, 1990, ASAIO transactions.

Life style and cardiovascular risk factors in the Japanese population--from an epidemiological survey on serum lipid levels in Japan 1990 part 1: influence of life style and excess body weight on HDL-cholesterol and other lipid parameters in men.

Toru Kita, Yasushi Saito, Y. Matsuzawa, 2003, Journal of atherosclerosis and thrombosis.

Site-directed mutagenesis of an apolipoprotein E mutant, apo E5(Glu3----Lys) and its binding to low density lipoprotein receptors.

A. Yamamoto, T. Yamamura, S. Tajima, 1992, Biochemical and biophysical research communications.

Enhanced binding activity of an apolipoprotein E mutant, APO E5, to LDL receptors on human fibroblasts.

A. Yamamoto, T. Yamamura, L. Dong, 1990, Biochemical and biophysical research communications.

Enhancement of non-polar lipid transfer reaction through stabilization of substrate lipid particles with apolipoproteins.

S. Yokoyama, A. Yamamoto, O. Nishikawa, 1988, Journal of biochemistry.

Prevalence of metabolic syndrome in the general Japanese population in 2000.

Y. Ouchi, Y. Matsuzawa, T. Kita, 2006, Journal of atherosclerosis and thrombosis.

Risk factors for coronary heart disease in the Japanese--comparison of the background of patients with acute coronary syndrome in the ASPAC study with data obtained from the general population. Asia-Pacific Collaboration on CHD Risk Factor Intervention study.

S. Hosoda, A. Keech, M. Nobuyoshi, 2002, Journal of atherosclerosis and thrombosis.

Life style and cardiovascular risk factors in the Japanese population--from an epidemiological survey on serum lipid levels in Japan 1990 part 2: association of lipid parameters with hypertension.

Y. Matsuzawa, T. Kita, H. Mabuchi, 2003, Journal of atherosclerosis and thrombosis.

Therapeutic effects of ML-236B in primary hypercholesterolemia.

A. Endo, A Endo, A. Yamamoto, 1980, Atherosclerosis.

Behavior of apolipoprotein C-II in an aqueous solution.

S. Yokoyama, Y. Kawai, A. Yamamoto, 1982, Journal of biochemistry.

Update of Japanese common LDLR gene mutations and their phenotypes: Mild type mutation L547V might predominate in the Japanese population.

Y. Kokubo, T. Miyata, N. Sakai, 2009, Atherosclerosis.

Effect of nafamostat mesilate on bradykinin generation and hemodynamics during LDL apheresis.

M. Kuramochi, A. Yamamoto, S. Kojima, 1995, Artificial organs.

K. Kario, T. Miyata, A. Yamamoto, 1999, Thrombosis and Haemostasis.

[Genetic mutants of plasma apolipoprotein E--apo E-5 and apo E-Suita--associated with hyperlipidemia and atherosclerosis].

S. Yokoyama, T. Sumiyoshi, A. Yamamoto, 1985, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine.

Intravascular free tissue factor pathway inhibitor is inversely correlated with HDL cholesterol and postheparin lipoprotein lipase but proportional to apolipoprotein A-II.

M. Yamagishi, H. Nonogi, K. Miyatake, 2000, Arteriosclerosis, thrombosis, and vascular biology.

Deletion of the Growth Factor Homology Domain of the Low Density Lipoprotein Receptor in Familial Hypercholesterolemia

T. Funahashi, S. Tajima, A. Yamamoto, 1990 .

Purification and characterization of lipoprotein lipase from human postheparin plasma and its comparison with purified bovine milk lipoprotein lipase.

A. Yamamoto, S. Tajima, R. Hayashi, 1986, Journal of biochemistry.

Uptake of oxidized low-density lipoprotein in a THP-1 cell line lacking scavenger receptor A.

M. Harada‐Shiba, A. Yamamoto, T. Yamamura, 2001, Atherosclerosis.

Apolipoprotein E polymorphism and coronary heart disease.

A. Yamamoto, T. Yamamura, L. Dong, 1992, Chinese medical journal.

Modulation of cholesterol microenvironment with apolipoproteins induced by the presence of cholesteryl ester in lipid microemulsion.

S. Yokoyama, A. Yamamoto, H. Okabe, 1988, Journal of biochemistry.

Association of apolipoprotein A-II with egg phosphatidylcholine unilamellar vesicles.

S. Yokoyama, A. Yamamoto, S. Tajima, 1984, Journal of biochemistry.

Rebound Curve Following LDL-Apheresis Reflects Catabolic Rate of Plasma Cholesterol And The Synthetic Rate of Lp(A)

M. Harada‐Shiba, A. Yamamoto, S. Kojima, 1996 .